Trasplante pulmonar en pacientes con fibrosis pulmonar. Experiencia del Instituto Nacional del Tórax
| Autor: | Erika Donoso G., Joel Melo T, Pedro Undurraga M., Catalina Briceño V., Claudia Sepúlveda L, Francesca Gajardo Z., Jaqueline López R., Mauricio Salinas F, Víctor Leiva V., Virginia Linacre S |
|---|---|
| Jazyk: | Spanish; Castilian |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Lung business.industry Trasplante pulmonar fibrosis pulmonar idiopática medicine.medical_treatment Interstitial lung disease General Medicine medicine.disease estudios de seguimiento Surgery Idiopathic pulmonary fibrosis FEV1/FVC ratio medicine.anatomical_structure Pulmonary fibrosis medicine Lung transplantation tasa de supervivencia business Survival rate Lung allocation score |
| Zdroj: | Revista chilena de enfermedades respiratorias v.35 n.1 2019 SciELO Chile CONICYT Chile instacron:CONICYT |
| Popis: | Pulmonary fibrosis is a progressive disease with a bad prognosis. This situation makes rise lung transplant as a therapeutic option among carefully selected patients. Objective: Evaluate the results and survival rates of patients with pulmonary fibrosis that were transplanted through an 8 years period of follow-up, from the beginning of our transplant program. Methods: Descriptive study of the transplanted patients diagnosed with pulmonary fibrosis from august 2010 to july 2018. Results: Out of 76 transplants, 68.4% were due to pulmonary fibrosis, among these, the main diagnosis was idiopathic pulmonary fibrosis (75%). The average lung allocation score (LAS) was 53 and 32% of them had urgency criteria. Patients’ age averaged 55 years-old and 98% of them underwent a single lung transplant. Early medical complications were seen in 26 patients with infectious episodes and 6 with acute rejection. The main late complication was chronic allograft dysfunction. The main surgical complication was bronchial stenosis (7.6%). In comparison to its base line reference values FVC means pre transplant and 1 and 3 years post-transplant were 49%, 70% and 71% respectively. A 40% of patients died during follow up period. Infections were the main cause of mortality during the first year. Survival rates at 1st 3rd and 5th year were 86,2%; 65.2% and 59.8% respectively. Conclusions: Single lung transplant is a therapeutic option for patients with interstitial lung disease with a 59% survival rate in 5 years, 1/3 fulfilled urgency criteria at the transplant time. The infections were the main early complication and chronic graft dysfunction was the main late complication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|